SOURCE: BioElectronics Corporation

BioElectronics Corporation

June 15, 2009 15:51 ET

BioElectronics Announces Investor Conference Call

Management Team to Discuss FDA Filing, Status of Clinical Trials and Additional Planned 510(k) FDA Submissions

FREDERICK, MD--(Marketwire - June 15, 2009) - BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced its management team will host an investor conference call to discuss its recent application for FDA clearance, the status of clinical trials and additional FDA filings planned over the coming few months. The call will be held on Thursday, June 18th, at 4:15 PM (EDT).

On the call, Barry Eppley, MD, DMD will review the findings of the recently published study on the Allay Period Relief Patch for the treatment of dysmenorrhea. Additionally, Sheena Kong, MD, will discuss the commencement of a new clinical study on the use of ActiPatch for the treatment of lower back pain. The lower back pain study is expected to be one of the largest studies on lower back pain ever conducted.

To access the conference call, please dial (712) 432-0080 approximately 10 minutes prior to the start time and enter access code 404367# to be placed into the conference.

About BioElectronics Corporation

BioElectronics Corporation is the maker of ActiPatch® Therapy, RecoveryRx™ Devices, HealFast™ Therapy ( and the Allay™ family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see

Contact Information

  • Contact:
    For media enquiries, please contact:
    Joe Noel
    BioElectronics Corp.
    (925) 922-2560